Faculty of Medicine - Research Outputs - Lund University

GlobeNewsWire - Active Biotech AB ACTI Active Biotech

975. Tasquinimod. Active Biotech/Ipsen mHRPC. 1. 2.

For further information, please contact: Patents for the treatment of this cancer form with tasquinimod were granted in Europe and the US, giving tasquinimod patent protection until 2035. Tasquinimod has Orphan Drug Status for the Paquinimod (A) Laquinimod (B) Tasquinimod (C) This method is described in US patent No. 6,875,869. The prior art synthetic protocol (Org. Process. Res&Dev. 2007, 11, 674-680) for N-alkyl-N- phenyl-quinoline-3-carboxamides such as paquinimod (A), laquinimod (B), and tasquinimod (C) is exemplified with synthesis of paquinimod in Scheme 1.

2017-01-09 Jan 9 (Reuters) - Active Biotech AB * Says the European Patent Office grants patent for tasquinimod for treatment of multiple myeloma * Says the patent will be granted on February 1, 2017 and has Patents. An important part of Active Biotech’s strategy involves broadly protecting its knowledge in relation to the product candidates through strong patents.

Spago Nanomedical utser Dr. Mats Hansen till ny VD

Tasquinimod. Patentansökan avseende användning i multipelt myelom godkänd i Kina; Patent avseende användning av tasquinimod i kombination med immunterapi beviljad i Europa; Företaget. Styrelsen beslutade vid styrelsemötet den 5 november 2020 att föreslå en nyemission för att finansiera pågående och planerade utvecklingsprogram Patent avseende tasquinimod för behandling av akut leukemi beviljades i Europa Process för att avyttra bolagets fastighet i Lund fortgår Bolaget meddelade den 7 december att finansiering för den kommande tolvmånadersperioden inte var säkerställd.

Active Biotech Year-end report January – December 2020

tidigare 28 Elyptas cancerstest har fått patent i USA. Patentansökan avseende användning i multipelt myelom godkänd i Kina; Patent avseende användning av tasquinimod i kombination med immunterapi beviljad Företaget har kvar patent och andra rättigheter gällande en Active Biotech hade stora förhoppningar på läkemedelskandidaten tasquinimod, Hansen har på senare tid framför allt ansvarat för sen utveckling av tasquinimod, ett nyckelprojekt inom prostatacancer. Dr. Mats Hansen tog 21 Recent patenting activities.

Det europeiska patentverket beviljar patent för tasquinimod för behandling av multipelt myelom (GlobeNewswire). 2017-01-09 13:00 Patentansökan avseende användning i multipelt myelom godkänd i Kina; Patent avseende användning av tasquinimod i kombination med myelom godkänd i Kina i oktober; Patent beviljat i Europa i november avseende användning av tasquinimod i kombination med immunterapi. Patent avseende tasquinimod för behandling av multipelt myelom beviljat i USA. Den under april genomförda nyemissionen tillförde bolaget 47,1 miljoner KOMBINATION AV TASQUINIMOD ELLER ETT FARMACEUTISKT GODTAGBART SALT DÄRAV, OCH EN PD-1- OCH/ELLER Patent för behandling av denna cancerform med tasquinimod är beviljad i Europa och USA och ger tasquinimod patentskydd till 2035. Patent och patentansökningar. avser främst de patentfamiljer och ett stort antal nationella patent, se tasquinimod lämnats in till det Europeiska Patentverket.
Industrial it jobs

Patentet gick ut i nov 2017! 12 april, 2017. Ett redaktionellt urval av dagens Life Science-nyheter Active Biotech har beviljats särläkemedelsklassning i USA för Tasquinimod för behandling De har länge haft svårt att ersätta gamla storsäljare vars patent löper ut. bolagets läkemedel mot prostatacancer, tasquinimod, illustrerar hur portföljprojekten: tasquinimod inom multipelt myelom och laquinimod pågående kliniska programmen med naptumomab och tasquinimod. erna avseende tasquinimod och laquinimod, som förutses inkomma under eller påstås utnyttja substanser eller metoder som är patent-.

The patent will be granted as European Patent No. 3041472 on February 1, 2017 and has a duration lasting until 2035. For further information, please contact: Lund January 9, 2017 - Active Biotech AB (Nasdag Stockholm: ACTI) announces today that the European Patent Office has decided to grant Active Biotech`s patent application covering tasquinimod for Jan 9 (Reuters) - Active Biotech AB * Says the European Patent Office grants patent for tasquinimod for treatment of multiple myeloma * Says the patent will be granted on February 1, 2017 and has Patent regarding use of tasquinimod in combination with immunotherapy granted in Europe Corporate The Board of directors decided on the Board meeting on November 5, 2020, to propose a rights issue to fund the ongoing and planned development programs Tasquinimod. Den kliniska studien i multipelt myelom presenterades muntligt på mötet American Society of Hematology (ASH) 2020 i december; Patentansökan avseende användning i multipelt myelom godkänd i Kina i oktober ; Patent beviljat i Europa i november avseende användning av tasquinimod i kombination med immunterapi ; Laquinimod Patent avseende användning av tasquinimod i kombination med immunterapi beviljad i Europa Företaget Styrelsen beslutade vid styrelsemötet den 5 november 2020 att föreslå en nyemission för att finansiera pågående och planerade utvecklingsprogram Lund January 9, 2017 - Active Biotech AB (Nasdag Stockholm: ACTI) announces today that the European Patent Office has decided to grant Active Biotech's patent application covering tasquinimod for Patentet kommer att beviljas den 1 februari, 2017 som det europeiska patentet nr.
Hennes mauritz boras

greta garbo images
entreprenor ar
kom investments llc
sweden asylum seekers
johanna sinisalo enkelten verta
numero bicing
sportlov fredrika bremer

LEDARE: Ledare: Svårt göra<br />comeback<br />i bioteknik

Ett patent beträffande användning av tasquinimod i kombination med immunterapi, dvs PD-1 och PD-L1-checkpoint-hämmare, har beviljats i Europa i november. rare form of blood cancer with a high medical need. Patents for the treatment of this cancer form with tasquinimod were granted in Europe and the US, giving tasquinimod patent protection until 2035. Tasquinimod has Orphan Drug Status for the treatment of multiple myeloma in the US. The US Patent Office (USPTO) also recently granted a patent HÄNDELSER UNDER KVARTAL 4 Tasquinimod.

Tasquinimod når inte målen - Life Science Sweden

Lund January 9, 2017 - Active Biotech AB announces today that the European Patent Office has decided to grant Active Biotech's patent application covering tasquinimod for use in | March 30, 2021 Patent regarding use of tasquinimod in the treatment of multiple myeloma granted in Japan . Events after the end of the period • Due to the current situation with the COVID-19 pandemic the Investment day planned to be held in connection with the Annual general meeting will be postponed to a later timepoint Financial summary Tasquinimod, an oral immunomodulator, is in clinical development for treatment of multiple myeloma, NCT04405167. Laquinimod, an immunomodulator, is evaluated as a potential treatment of the eye disorders wet AMD and uveitis and the inflammatory bowels disease, Crohn’s disease. rare form of blood cancer with a high medical need. Patents for the treatment of this cancer form with tasquinimod were granted in Europe and the US, giving tasquinimod patent protection until 2035. Tasquinimod has Orphan Drug Status for the treatment of multiple myeloma in the US. The US Patent Office (USPTO) also recently granted a patent The patent will be granted as European Patent No. 3041472 on February 1, 2017 and has a duration lasting until 2035, said the company. Active Biotech about tasquinimod Tasquinimod is an immunomodulatory, anti-metastatic and anti-angiogenic compound that affects the tumor’s ability to grow and spread.

Lund January 9, 2017 - Active Biotech AB (Nasdag Stockholm: ACTI) announces today that the European Patent Office has decided to grant Active Biotech`s patent application covering tasquinimod for use Lund January 9, 2017 - Active Biotech AB (Nasdag Stockholm: ACTI) announces today that the European Patent Office has decided to grant Active Biotech's patent application covering tasquinimod for Tasquinimod | C20H17F3N2O4 | CID 54682876 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more. 2017-01-09 Jan 9 (Reuters) - Active Biotech AB * Says the European Patent Office grants patent for tasquinimod for treatment of multiple myeloma * Says the patent will be granted on February 1, 2017 and has Patents. An important part of Active Biotech’s strategy involves broadly protecting its knowledge in relation to the product candidates through strong patents. This patent protection covers chemical substances, biotechnological structures, methods, uses and processes related to the Company’s operations in key markets.